150 related articles for article (PubMed ID: 35243730)
1. Treatment of early-stage mycosis fungoides with oral bexarotene and phototherapy: A systematic review and meta-analysis.
Ginsburg E; Hennessy K; Mhaskar R; Seminario-Vidal L
Dermatol Ther; 2022 May; 35(5):e15418. PubMed ID: 35243730
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy and safety of bexarotene for Japanese patients with cutaneous T-cell lymphoma: The results of a phase 2 study (B-1201).
Hamada T; Tokura Y; Sugaya M; Ohtsuka M; Tsuboi R; Nagatani T; Kiyohara E; Tani M; Setoyama M; Matsushita S; Kawai K; Yonekura K; Saida T; Iwatsuki K
J Dermatol; 2019 Jul; 46(7):557-563. PubMed ID: 31090237
[TBL] [Abstract][Full Text] [Related]
3. Phototherapy for mycosis fungoides.
Dogra S; Mahajan R
Indian J Dermatol Venereol Leprol; 2015; 81(2):124-35. PubMed ID: 25751327
[TBL] [Abstract][Full Text] [Related]
4. Systematic review of combination therapies for mycosis fungoides.
Humme D; Nast A; Erdmann R; Vandersee S; Beyer M
Cancer Treat Rev; 2014 Sep; 40(8):927-33. PubMed ID: 24997678
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Narrowband UV-B With Psoralen-UV-A Phototherapy for Patients With Early-Stage Mycosis Fungoides: A Systematic Review and Meta-analysis.
Phan K; Ramachandran V; Fassihi H; Sebaratnam DF
JAMA Dermatol; 2019 Mar; 155(3):335-341. PubMed ID: 30698622
[TBL] [Abstract][Full Text] [Related]
6. Long-term control of mycosis fungoides of the hands with topical bexarotene.
Lain T; Talpur R; Duvic M
Int J Dermatol; 2003 Mar; 42(3):238-41. PubMed ID: 12653924
[TBL] [Abstract][Full Text] [Related]
7. Bexarotene therapy for mycosis fungoides and Sézary syndrome.
Abbott RA; Whittaker SJ; Morris SL; Russell-Jones R; Hung T; Bashir SJ; Scarisbrick JJ
Br J Dermatol; 2009 Jun; 160(6):1299-307. PubMed ID: 19222457
[TBL] [Abstract][Full Text] [Related]
8. Oral bexarotene for post-transplant cutaneous T-cell lymphoma.
Lewis DJ; Huang S; Duvic M
Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28748653
[TBL] [Abstract][Full Text] [Related]
9. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
10. Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma.
Sokolowska-Wojdylo M; Florek A; Zaucha JM; Chmielowska E; Giza A; Knopinska-Posluszny W; Kulikowski W; Prejzner W; Romejko-Jarosinska J; Paszkiewicz-Kozik E; Osowiecki M; Walewski J; Rogowski W; Grzanka A; Placek W; Lugowska-Umer H; Kowalczyk A; Nowicki R; Jurczak W
Am J Ther; 2016; 23(3):e749-56. PubMed ID: 24732904
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
Kannangara AP; Levitan D; Fleischer AB
J Dermatolog Treat; 2009; 20(3):169-76. PubMed ID: 19016373
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of bexarotene for Japanese patients with cutaneous T-cell lymphoma: Real-world experience from post-marketing surveillance.
Hamada T; Morita A; Suga H; Boki H; Fujimura T; Hirai Y; Shimauchi T; Tateishi C; Kiyohara E; Muto I; Nakajima H; Abe R; Fujii K; Nishigori C; Nakano E; Yonekura K; Funakoshi T; Amano M; Miyagaki T; Makita N; Manaka K; Shimoyama Y; Sugaya M
J Dermatol; 2022 Feb; 49(2):253-262. PubMed ID: 34658060
[TBL] [Abstract][Full Text] [Related]
13. [Bexarotene therapy in folliculotropic cutaneous T-cell lymphoma].
Drugeon C; Charlat I; Boulinguez S; Viraben R
Ann Dermatol Venereol; 2007; 134(8-9):639-43. PubMed ID: 17925686
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of interferon α-2a combined with phototherapy for patients with early-stage mycosis fungoides - a single-arm prospective study in 13 patients.
Song H; Hu Z; Zhang S; Yang L; Feng J; Lu L; Liu Y; Wang T
J Dermatolog Treat; 2024 Dec; 35(1):2350231. PubMed ID: 38754985
[No Abstract] [Full Text] [Related]
15. Childhood mycosis fungoides: experience of 28 patients and response to phototherapy.
Laws PM; Shear NH; Pope E
Pediatr Dermatol; 2014; 31(4):459-64. PubMed ID: 24916067
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Early Folliculotropic Mycosis Fungoides with Special Focus on Psoralen plus Ultraviolet A.
Amitay-Laish I; Prag-Naveh H; Dalal A; Pavlovsky L; Feinmesser M; Hodak E
Acta Derm Venereol; 2018 Nov; 98(10):951-955. PubMed ID: 30085321
[TBL] [Abstract][Full Text] [Related]
17. Interventions for mycosis fungoides.
Weberschock T; Strametz R; Lorenz M; Röllig C; Bunch C; Bauer A; Schmitt J
Cochrane Database Syst Rev; 2012 Sep; (9):CD008946. PubMed ID: 22972128
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056).
Whittaker S; Ortiz P; Dummer R; Ranki A; Hasan B; Meulemans B; Gellrich S; Knobler R; Stadler R; Karrasch M
Br J Dermatol; 2012 Sep; 167(3):678-87. PubMed ID: 22924950
[TBL] [Abstract][Full Text] [Related]
19. Bexarotene and narrowband ultraviolet B phototherapy combination treatment for mycosis fungoides.
Lokitz ML; Wong HK
Photodermatol Photoimmunol Photomed; 2007 Dec; 23(6):255-7. PubMed ID: 17986063
[TBL] [Abstract][Full Text] [Related]
20. Plaque stage mycosis fungoides treated with bexarotene at low dosage and UVB-NB.
D'Acunto C; Gurioli C; Neri I
J Dermatolog Treat; 2010 Jan; 21(1):45-8. PubMed ID: 19603308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
